Previous 10 | Next 10 |
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s Chief Financial Officer, Reinhar...
2024-01-29 10:43:48 ET More on HOOKIPA Pharma Hookipa Pharma stock soars on $21.25M equity investment from Gilead HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Histori...
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milest...
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Devel...
2023-12-21 09:55:17 ET DENVER, Colo., Dec. 21, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; HOOKIPA Pharma Inc (NASDAQ: HOOK), ParaZero Technologies Ltd (NASDAQ: PRZO), Atara Biotherapeutics Inc (NASDA...
2023-12-21 09:03:14 ET More on HOOKIPA Pharma HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earnings data for HOOKIPA Pharma Financial information for HOOKI...
2023-12-21 08:50:38 ET DENVER, Colo., Dec 21, 2023 ( www.247marketnews.com )- HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported, this morning, that Gilead Sciences, Inc. (NASDAQ: GILD) purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of...
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partner...
News, Short Squeeze, Breakout and More Instantly...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. ...